price
RG
NASDAQ · RGNX
REGENXBIO Inc.
Healthcare · Biotechnology
$7.43
Up+$0.01 (+0.13%)
Updated Oct 3, 2026, 10:44 AM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 650.96M
- P/E ratio
- -3.74
- Dividend yield
- 0.00%
- 52-week range
- $5.46 – $15.88
- Volume
- 1.05M
- Avg. volume
- 586.76K
Price performance · RGNX
RGNX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
RGNX closed at $7.43 after 20 trading sessions, down 16.89% for the selected period.
- Last close
- $7.43
- Period change
- -16.89%
- Period low
- $7.24
- Period high
- $8.94
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $7.58 | $7.62 | $7.36 | $7.43 | 1.05M |
| Oct 1, 2026 | $7.52 | $7.7363 | $7.30 | $7.42 | 1.71M |
| Sep 30, 2026 | $7.49 | $7.86 | $7.35 | $7.53 | 1.79M |
| Sep 29, 2026 | $7.41 | $7.64 | $7.33 | $7.45 | 2.1M |
| Sep 28, 2026 | $7.30 | $7.495 | $7.1701 | $7.47 | 1.33M |
| Sep 25, 2026 | $7.53 | $7.675 | $7.165 | $7.40 | 1.28M |
| Sep 24, 2026 | $7.45 | $7.46 | $7.12 | $7.24 | 1.52M |
| Sep 23, 2026 | $8.13 | $8.145 | $7.40 | $7.50 | 1.11M |
| Sep 22, 2026 | $8.03 | $8.25 | $7.9041 | $8.15 | 1.2M |
| Sep 21, 2026 | $8.24 | $8.3132 | $7.76 | $7.88 | 1.12M |
| Sep 18, 2026 | $8.22 | $8.331 | $8.00 | $8.03 | 3.38M |
| Sep 17, 2026 | $8.34 | $8.56 | $8.02 | $8.215 | 1.81M |
| Sep 16, 2026 | $7.93 | $7.99 | $7.6359 | $7.98 | 1.23M |
| Sep 15, 2026 | $8.69 | $8.75 | $7.78 | $7.945 | 1.43M |
| Sep 14, 2026 | $8.58 | $8.7276 | $8.49 | $8.69 | 858.45K |
| Sep 11, 2026 | $8.69 | $8.82 | $8.39 | $8.53 | 1.03M |
| Sep 10, 2026 | $8.63 | $8.79 | $8.47 | $8.56 | 1.17M |
| Sep 9, 2026 | $8.70 | $9.025 | $8.62 | $8.73 | 1.41M |
| Sep 8, 2026 | $8.95 | $8.95 | $8.60 | $8.76 | 998.96K |
| Sep 4, 2026 | $9.09 | $9.215 | $8.86 | $8.94 | 1.07M |
Latest RGNX news
The latest Smart Investors Daily articles mentioning RGNX.
Stock researchResearch & News · SEC Filings
Company
Market Activity
Research & News
Loading stock research…